Department of Rheumatology & Immunology and Beijing Key Laboratory for Rheumatism and Immune Diagnosis (BZ0135), Peking University People's Hospital, 11 Xizhimen South Street, Beijing, 100044, China.
Center of Clinical Immunology, Peking University, Beijing, 100044, China.
Arthritis Res Ther. 2021 Oct 15;23(1):261. doi: 10.1186/s13075-021-02638-0.
Remitting seronegative symmetrical synovitis with pitting edema (RSPE) is a rare inflammatory arthritis, with a higher incidence of malignancy. The aim of this study is to identify biomarkers for predicting malignancy in RSPE.
A total of 51 patients with RSPE from September 2007 to May 2019 were retrospectively reviewed and followed for up to 5 years, with 15 patients with osteoarthritis (OA) and 14 patients with elderly-onset rheumatoid arthritis (EORA) as disease controls. Serum levels of angiogenesis cytokines were measured by electrochemiluminescent immunoassay and Luminex Human Magnetic Assay. Clinical data and laboratory parameters were analyzed to identify risk factors for malignancy.
A total of forty-eight RSPE patients (94.1%) were available with follow-up data; 8 patients (16.7%) were diagnosed with malignancy, of which 6 patients were hematological tumor; and 2 patients were solid tumors. Serum levels of basic fibroblast growth factor (bFGF) were exclusively higher in RSPE patients with malignancy [14.21 (7.52, 23.18) ng/mL] than RSPE patients without malignancy [4.32 (2.88, 7.42) ng/mL], OA [3.20 (2.20, 5.30) ng/mL], and EORA [3.20 (2.20, 5.30) ng/mL]. The optimal cut-off value of bFGF for malignancy was 10ng/mL in RSPE. Logistic regression analysis indicated that elevation of bFGF was a risk factor for malignancy in RSPE.
This study indicated that bFGF was elevated in RSPE patients with malignancy and could serve as a biomarker for predicting paraneoplastic RSPE.
缓解性血清阴性对称性滑膜炎伴凹陷性水肿（RSPE）是一种罕见的炎性关节炎，其恶性肿瘤发病率较高。本研究旨在确定预测 RSPE 恶性肿瘤的生物标志物。
回顾性分析 2007 年 9 月至 2019 年 5 月间 51 例 RSPE 患者，随访时间最长 5 年，以 15 例骨关节炎（OA）和 14 例老年发病类风湿关节炎（EORA）患者为疾病对照。采用电化学发光免疫分析和 Luminex 人磁珠法检测血管生成细胞因子的血清水平。分析临床资料和实验室参数，以确定恶性肿瘤的危险因素。
共 48 例 RSPE 患者（94.1%）获得随访数据，8 例（16.7%）患者诊断为恶性肿瘤，其中 6 例为血液系统肿瘤，2 例为实体肿瘤。恶性肿瘤 RSPE 患者血清碱性成纤维细胞生长因子（bFGF）水平明显高于无恶性肿瘤 RSPE 患者[14.21（7.52，23.18）ng/ml]、OA [3.20（2.20，5.30）ng/ml]和 EORA [3.20（2.20，5.30）ng/ml]。RSPE 患者 bFGF 预测恶性肿瘤的最佳截断值为 10ng/ml。Logistic 回归分析表明，bFGF 升高是 RSPE 恶性肿瘤的危险因素。
本研究表明，RSPE 合并恶性肿瘤患者 bFGF 升高，可作为预测副肿瘤性 RSPE 的生物标志物。
